Clinical trials: Psoriasis Patients
Rheumatoid Arthritis, Psoriatic Arthritis
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis (RA), psoriatic arthritis(PsA), axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis
- Trial name
- ADEQUATE (NCT02486302)
- Testing
- Etanercept
- Where
- 180 sites in Germany
- Volunteers
- 1,534 people
- Sponsor
- Pfizer
Psoriasis
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05536726
- Testing
- 608 Q2W, 608 Q4W
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque…
- Trial name
- HB0017 (NCT06592274)
- Testing
- HB0017
- Where
- 18 sites in China
- Volunteers
- 206 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Parapsoriasis
Natural Gels for Treatment of Plaque Psoriasis
The aim of the study is to evaluate the safety and the therapeutic activity of the combination of Natural Gel combination and hair mask of plant origin in patients with mild to moderate plaque psoriasis.
- Trial name
- NCT02330237
- Testing
- natural gels
- Where
- Israel
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Secret of Youth
Psoriasis
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment.
- Trial name
- NCT02203851
- Testing
- Risankizumab
- Volunteers
- 110 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriatic Arthritis
A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis
The study is a Worldwide Survey on the Understanding of Psoriatic Disease among Patients with Psoriasis and Psoriatic Arthritis.
- Trial name
- NCT04614831
- Where
- Switzerland
- Volunteers
- 4,978 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Taltz in Combination With Enstilar for Psoriasis
Enstilar in combination with Taltz for plaque psoriasis.
- Trial name
- NCT04372277
- Testing
- Enstilar
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Psoriasis
Use of Serum M2BP and MSUS to Predict Arthritis in Psoriatic Patients
Aims of the study: 1. Measurement of serum level of Mac 2 binding protein among patients with psoriasis, psoriatic arthritis and subclinical psoriatic arthritis compared with healthy individuals. 2.
- Trial name
- NCT04435730
- Testing
- serum level of Mac 2 binding protein, musculoskeletal ultrasound
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assiut University
Plaque Psoriasis
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease.
- Trial name
- NCT03168256
- Testing
- CF101 2mg, CF101 3mg, Apremilast 30mg
- Where
- 30 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 528 people
- Sponsor
- Can-Fite BioPharma
Plaque Psoriasis
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed to compare efficacy, safety, immunogenicity, and PK of BAT2306 with Cosentyx in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05377944
- Testing
- BAT2306, EU-approved Cosentyx
- Where
- China
- Volunteers
- 502 people
- Sponsor
- Bio-Thera Solutions
Plaque Psoriasis
A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara® in patients with Moderate-to-Severe Plaque Psoriasis.
- Trial name
- VESPUCCI (NCT04595409)
- Testing
- FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)
- Where
- 16 sites in Estonia, Georgia and 2 more
- Volunteers
- 392 people
- Sponsor
- Bioeq GmbH
Psoriasis Vulgaris, Autophagy
ATG5 as a Serum Marker of Autophagy in Psoriatic Patient
it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.
- Trial name
- NCT05279638
- Testing
- serum ATG5
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sohag University
Psoriasis
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type…
- Trial name
- POLARIS (NCT02951533)
- Testing
- Guselkumab, Fumaric Acid Esters
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Janssen-Cilag G.m.b.H
Psoriatic Arthritis
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- FUTURE 1 (NCT01392326)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 110 sites in United States, Argentina and 17 more
- Volunteers
- 606 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
The main aim of the study is to evaluate the efficacy, safety and impact on the health-related quality of life (HRQoL) in participants with moderate-to-severe chronic plaque psoriasis who are treated with tildrakizumab 100…
- Trial name
- TRIBUTE (NCT04229836)
- Testing
- Tildrakizumab 100 mg Solution for Injection
- Where
- 39 sites in Italy, Spain
- Volunteers
- 178 people
- Sponsor
- Almirall, S.A.
Influenza, Rheumatic Diseases
Vaccination Against Influenza H1N1 in Rheumatic Diseases
The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1.
- Trial name
- NCT01006681
- Testing
- Focetria (Monovalent MF59-Adjuvanted vaccine)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Psoriasis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.
- Trial name
- UNCOVER-1 (NCT01474512)
- Testing
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,296 people
- Sponsor
- Eli Lilly and Company
Psoriasis Vulgaris
Body PSOriasis: Long-term Relapse CONTROL
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow…
- Trial name
- PSO-CONTROL (NCT03402828)
- Testing
- Any topical drug treatment
- Where
- Russia
- Volunteers
- 764 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05600036
- Testing
- ESK-001
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 228 people
- Sponsor
- Alumis Inc
Arthritis, Rheumatoid, Arthritis, Psoriatic
A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
- Conditions
- Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing
- Trial name
- GO-NICE (NCT01313858)
- Testing
- Simponi®, Methotrexate
- Volunteers
- 1,613 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.